Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RMTI with free AI briefings, catalyst countdowns, and dilution alerts.

RMTI · ROCKWELL MEDICAL, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$22.5M Cash on Hand
CF+ Cash Runway
Follow RMTI by email Get an email when RMTI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RMTI, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Citrate
FDA approved Jan 2015 · Triferic (discontinued)
Iron-Refractory Iron-Deficiency Anemia Phase 2 · NCT02905981 Terminated
Triferic AVNU End Stage Renal Disease Phase 4 · NCT04689932 Completed
SFP End Stage Renal Disease Phase 3 · NCT01503021 Completed
Soluble ferric pyrophosphate Renal Failure Chronic Requiring Hemodialysis Phase 3 · NCT01322347 Completed
Triferic End Stage Renal Disease Phase 3 · NCT04239391 Unknown
Erythrocyte Stimulating Agent (ESA) End Stage Renal Disease Phase 2 · NCT01286012 Completed
Fer-In-Sol Iron-Refractory Iron-Deficiency Anemia Phase 2 · NCT02905981 Terminated
Heparin End Stage Renal Disease Phase 1/2 · NCT04042324 Completed
Iron End Stage Renal Disease Phase 2 · NCT01286012 Completed
Soluble Ferric Pyrophosphate in liquid… End Stage Renal Disease Phase 2 · NCT01286012 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RMTI holds $22.5M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RMTI files for a raise →

👥 Who Owns RMTI

Insiders 10.7% Institutions (40 holders) 8.5% Public and other holders 80.8%
HolderTypeShares% of sharesAs of
Mark H Ravich
Director
Insider 151,103 3.75% 2025-05-20
Mark Strobeck
President and CEO, Director · +352,000 options
Insider 61,349 1.52% 2026-10-01
Megan C. Timmins
EVP, CLO & Secretary · +97,500 options
Insider 31,240 0.78% 2026-07-01
Heather Hunter
Chief Operating Officer
Insider 28,007 0.69% 2026-07-01
Timothy Chole
SVP and CCO · +85,000 options
Insider 27,285 0.68% 2026-07-01
Jesse Neri
SVP and CFO · +97,500 options
Insider 27,239 0.68% 2026-07-01
Robert S Radie
Director
Insider 23,985 0.60% 2026-07-01
Allen Nissenson
Director
Insider 23,892 0.59% 2026-07-01
John G Cooper
Director
Insider 23,670 0.59% 2026-07-01
Joan Lau
Director
Insider 20,944 0.52% 2026-07-01
Joseph H Dawson
Director · +25,000 options
Insider 12,133 0.30% 2026-07-01

Share count 4,030,465 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RMTI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RMTI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.